What is the role of onabotulinumtoxinA (Botox) in the treatment of cauda equina and conus medullaris syndrome?

Updated: Jun 14, 2018
  • Author: Segun Toyin Dawodu, JD, MD, MS, MBA, LLM, FAAPMR, FAANEM; Chief Editor: Nicholas Lorenzo, MD, CPE, MHCM, FAAPL  more...
  • Print

In August 2011, onabotulinumtoxinA was approved by the US Food and Drug Administration for urinary incontinence in patients with neurologic conditions (eg, spinal cord injury, multiple sclerosis) who have overactive bladder. Therapy consists of 30 intradetrusor injections via cystoscopy. Trials have shown patients who received onabotulinumtoxinA had significant reduction in urinary incontinence episodes and improved urodynamics compared with placebo at 12 weeks. [93, 94, 95]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!